

**AMENDMENT AND PRESENTATION OF CLAIMS**

Please replace all prior claims in the present application with the following claims, in which claims 3-5, 8, 10-12, 14 and 15 are currently amended.

1. (Original) A laminate comprising a transparent type I collagen sheet and a cultured layer of human corneal endothelial cells provided on said sheet.

2. (Original) The laminate according to claim 1, wherein the transparency of said transparent type I collagen sheet is maintained under physiological conditions.

3. (Currently Amended) The laminate according to claim 1 [[or 2]], wherein said transparent type I collagen sheet has an adhesive factor or bioadhesive layer on the opposite side from the cultured layer of human corneal endothelial cells.

4. (Currently Amended) The laminate according to ~~any of claims 1 to~~ claim 3, wherein an adhesive factor or bioadhesive layer is provided between said transparent type I collagen sheet and said cultured layer of human corneal endothelial cells.

5. (Currently Amended) The laminate according to claim 3 [[or 4]], wherein said adhesive factor is human plasma fibronectin.

6. (Original) A method for manufacturing a laminate of cultured human corneal endothelial cells layer comprising:

preparing a transparent type I collagen sheet; and

culturing human corneal endothelial cells on said sheet to form a cultured layer of human corneal endothelial cells.

7. (Original) The method according to claim 6 wherein the transparency of said transparent type I collagen sheet is maintained under physiological conditions.

8. (Currently Amended) The method according to claim 6 [[or 7]], wherein said human corneal endothelial cells are cultured on a transparent type I collagen sheet that has been coated with an adhesive factor or a bioadhesive.

9. (Original) The method according to claim 8, wherein said adhesive factor is human plasma fibronectin.

10. (Currently Amended) The method according to ~~any of claims~~ claim 6 [[to 9]], wherein said human corneal endothelial cells are cultured after providing a culture solution containing human corneal endothelial cells on a transparent type I collagen sheet and applying centrifugal force in the direction of said transparent type I collagen sheet.

11. (Currently Amended) The method according to ~~any of claims~~ claim 6 [[to 9]], wherein in the culturing of said human corneal endothelial cells, the concentration of said human corneal endothelial cells in a culture solution is set to within a range of from  $1 \times 10^5$  to  $1 \times 10^7$  cells /mL.

12. (Currently Amended) The method according to ~~any of claims~~ claim 6 [[to 9]], wherein said corneal endothelial cells are cells that have been passaged.

13. (Original) The method according to claim 12, wherein the passage is conducted for 2 to 10 generations.

14. (Currently Amended) The method according to ~~any of claims~~ claim 6 [[to 9]], wherein said corneal endothelial cells are cultured under conditions of 37°C and 10 percent CO<sub>2</sub>.

15. (Currently Amended) The method according to ~~any of claims~~ claim 6 [[to 9]], wherein the culturing is conducted using a cell culturing solution comprising fetal bovine serum, growth factor, and hyaluronic acid in a medium of low glucose concentration.